EMD Millipore Launches OsteoMAX-XF™, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium

Product News   May 09, 2013

 
EMD Millipore Launches OsteoMAX-XF™, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium
 
 
FURTHER INFORMATION
 
 
 

Related Product News

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company

Product News

Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic reference standards, and cell therapy.

READ MORE

Lonza Expands Cell-Culture Portfolio with Quasi Vivo® System

Product News

The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies.

READ MORE

QIAGEN’s QuantiFERON-TB Gold Plus Gains Approval in Japan

Product News

QIAGEN N.V. announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection.

READ MORE

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE